pharmaphorum

SEPTEMBER 14, 2020

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. While it is a very rare form of epilepsy, it is such a cheap and harmless medication that it is often used as a first-line therapy for infants in intensive care who have no genetic diagnosis.

Genomics 119

Genomics Genome Medicine Gene 119

Scienmag

OCTOBER 22, 2020

Poop contains very precise information about the prey […]. For scientists, digging into feces provides insights into animal diets and is particularly useful for understanding nocturnal or rare species. When animals eat, prey DNA travels all the way through animal digestive tracts and comes out again.

DNA 54

DNA Containment Scientist Bioinformatics 54

The Pharma Data

JULY 27, 2021

This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. About Teneobio Teneobio, Inc.

Production 52

Production Antibody Sales Development 52

The Pharma Data

OCTOBER 27, 2020

the phase 2 SAPPHIRE study seeks to evaluate the use of autologous endothelial progenitor cells (EPCs) genetically engineered to express endothelial nitric oxide synthase in patients with PAH taking conventional PAH treatments. . Autologous cell therapy for PAH — SAPPHIRE. Conducted by our Canadian affiliate Northern Therapeutics, Inc.,

Production 40

Production Sales Licensing Licensing 40

XTalks

NOVEMBER 7, 2022

Dr. Bahassi explained that technological advances in genetic sequencing of cfDNA have enabled liquid biopsies and led to marked increase in the detection of therapeutically-targetable mutations. Optimal methods for bioinformatic analysis are still needed. percent show less reliability). Exosome-Based Liquid Biopsy in Oncology.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

DECEMBER 13, 2023

3) Fulgent Genetics Compound annual growth rate: 260 percent Fulgent Genetics, headquartered in California, is a technology-driven company with a strong presence in clinical diagnostics and therapeutic development. The company achieved core revenues of $67 million, reflecting a remarkable 48 perecent year-over-year growth.

Genetics 111

Genetics Vaccine Vaccination DNA 111